---
reference_id: "PMID:32179957"
title: "[Gene-selective treatment approaches for Huntington's disease]."
authors:
- Mühlbäck A
- Lindenberg KS
- Saft C
- Priller J
- Landwehrmeyer GB
journal: Nervenarzt
year: '2020'
doi: 10.1007/s00115-020-00882-4
content_type: abstract_only
---

# [Gene-selective treatment approaches for Huntington's disease].
**Authors:** Mühlbäck A, Lindenberg KS, Saft C, Priller J, Landwehrmeyer GB
**Journal:** Nervenarzt (2020)
**DOI:** [10.1007/s00115-020-00882-4](https://doi.org/10.1007/s00115-020-00882-4)

## Content

1. Nervenarzt. 2020 Apr;91(4):303-311. doi: 10.1007/s00115-020-00882-4.

[Gene-selective treatment approaches for Huntington's disease].

[Article in German]

Mühlbäck A(1)(2), Lindenberg KS(1), Saft C(3), Priller J(4), Landwehrmeyer 
GB(5).

Author information:
(1)Abteilung Neurologie, Universitätsklinikum Ulm, Oberer Eselsberg 45/1, 89081, 
Ulm, Deutschland.
(2)Klinik für Neurologie und Zentrum für klinische Neurowissenschaften, 1. 
Medizinische Fakultät, Karlsuniversität, Prag, Tschechien.
(3)Huntington-Zentrum NRW, Neurologische Klinik der Ruhr-Universität Bochum, St. 
Josef-Hospital, Bochum, Deutschland.
(4)Klinik für Psychiatrie und Psychotherapie, Charité Universitätsmedizin 
Berlin, Berlin, Deutschland.
(5)Abteilung Neurologie, Universitätsklinikum Ulm, Oberer Eselsberg 45/1, 89081, 
Ulm, Deutschland. bernhard.landwehrmeyer@uni-ulm.de.

In Germany at least 8000 and probably up to ca. 14,000 people currently suffer 
from clinically manifest Huntington's disease (HD). In addition, an estimated 
24,000 Germans carry the HD mutation in the huntingtin (HTT) gene and will 
develop HD during their lifetime. Although HD is a rare neurodegenerative 
disease, it is currently in the focus of general medical interest: clinical 
trials have begun that provide a rational basis for hope to slow down the so far 
relentless progression of the disease, ultimately resulting in patients becoming 
entirely dependent on nursing care. If treatment is started early enough it may 
be possible to mitigate the clinical manifestation of HD. These innovative 
therapeutic approaches aim at inhibiting the de novo production of mutant HTT 
gene products. A first clinical drug trial to demonstrate the efficacy 
(phase III) of intrathecal antisense oligonucleotides (ASO, active substance 
RG6042) was started in 2019. Additional clinical studies on alternative 
treatment approaches with allele-selective ASOs as well as gene therapeutic 
approaches using RNA molecules and zinc finger repressor complexes are imminent. 
This article gives an overview of the current gene-selective therapeutic 
approaches in HD under discussion.

DOI: 10.1007/s00115-020-00882-4
PMID: 32179957 [Indexed for MEDLINE]